Pfizer remains an undervalued stock that has underperformed the market but increased 2% since the last analysis. It is viewed as a defensive holding that provides income and helps offset risks related to AI in a diversified portfolio. Despite recent underperformance, the outlook remains bullish due to Pfizer's strategic role and income potential. The analyst emphasizes Pfizer's value as a cautious investment in volatile markets rather than a high-growth stock.
Pfizer is currently undervalued, trading at just over 8 times its projected 2026 earnings and offering a 7% dividend yield. Its core business, excluding COVID-related drugs, grew 7% in Q1, while new products, especially from its acquisition of Seagen...
The global Transthyretin Amyloidosis Treatment Market, valued at $8.95 billion in 2025, is projected to reach $35.10 billion by 2035 with a CAGR of 14.64%. Growth is fueled by advances in gene-silencing RNAi therapies like patisiran and vutrisiran, i...
The global Transthyretin Amyloidosis Treatment Market, valued at $8.95 billion in 2025, is projected to grow to $35.10 billion by 2035 at a CAGR of 14.64%. Growth is fueled by advances in gene-silencing drugs like patisiran and vutrisiran, improved d...
